Global Life Sciences
Overview
Featured News & Insights
0015
Contacts
Services
Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, we can offer you a holistic legal approach that will smooth your path as you navigate industry changes, technological advances, market demands and policy hurdles.
Regions
From high-profile transactions to regulatory issues and complex litigation, we collaborate across borders and disciplines to help our clients in more than 70 countries face challenges and embrace opportunities.

All Professionals
sort


Capabilities
- Antitrust and Competition
- Capital Markets
- Commercial Litigation and Disputes
- Emerging Companies and Venture Capital
- Environmental, Health, and Safety
- Food, Drug and Medical Device
- Global Arbitration, Trade and Advocacy
- Government Strategies
- Healthcare
- IP Litigation
- M&A
- Privacy and Cybersecurity
- Private Equity
- Product Liability and Mass Torts
- Technology
- Technology and Life Sciences Transactions
Related Resources
Related Blogs
News & Insights
Sidley & Trinity Capital Life Sciences ReceptionThursday, October 22, 2026California Adopts Regulations Expanding Healthcare Transaction ReviewOctober 8, 20262025 to First-Half 2026 Marks a Breakout Time for CVRsOctober 7, 2026Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026
Receptions
Global Life Sciences Update
GoodLifeSci
Announcements
California Adopts Regulations Expanding Healthcare Transaction ReviewOctober 8, 2026Congressional Democrats Propose First Federal Corporate Practice of Medicine Law; Unlikely to PassOctober 6, 2026GLOBE MFN (Most-Favored-Nation) Drug Pricing for Medicare Part B Significantly Narrowed in Final RuleOctober 5, 2026U.S. Department of Justice Announces Major Justice Manual Revisions on Sub-Regulatory Guidance and Dismissals of False Claims Act Qui TamsSeptember 21, 2026
Global Life Sciences Update
Global Life Sciences Update
Global Life Sciences Update
Healthcare Update
A Breakout Year for CVRs: 2025 and First-Half 2026 Trends in Life Sciences Public M&AOctober 6, 2026Texas Medicaid Fraud Decision Leaves 2 Open QuestionsOctober 1, 2026New York Ethics Opinion Warns Lawyers on Qui Tam DeceptionSeptember 2, 2026Recent ESG Developments in EuropeAugust 2026
Publications
Law360
Law360
Sidley Life Sciences Briefing
Good Manufacturing Practice 2026Wednesday, December 2, 2026A New World Order – Market Access, MFN, and GeopoliticsTuesday, November 10, 2026Sidley & Trinity Capital Life Sciences ReceptionThursday, October 22, 2026Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026
Events
Events
Receptions
Conferences
Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITMOctober 5, 2026Sidley Represents SlateView Capital in Its Joint Venture’s Acquisition of Parkview Estates in Southern CaliforniaOctober 5, 2026Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public OfferingOctober 1, 2026
Announcements
Announcements
Announcements
Announcements
Sidley Wins Seven Honors at the 2026 LMG Life Sciences Americas AwardsSeptember 11, 2026Managing IP Recognizes Sidley and 12 Lawyers in IP Stars 2026July 31, 2026Sidley Shortlisted in 16 Categories at the LMG Life Sciences Americas Awards 2026July 20, 2026Sidley Highly Ranked in Chambers USA 2026June 4, 2026
Accolades
Accolades
Accolades
Accolades
2025 to First-Half 2026 Marks a Breakout Time for CVRsOctober 7, 2026EU Biotech Act I: Parliament and Council back Europe’s biotech competitiveness agenda – SPC incentive now the key battlegroundSeptember 21, 2026HHS Secretary Announces Intent to Extend HHS-OIG Exclusion Authority to CMS, Expanding the Administration’s Anti-Fraud CampaignSeptember 16, 2026When AI Changes The Deal: Seven AI-related Considerations for Life Sciences M&A DealmakersSeptember 8, 2026
GoodLifeSci
GoodLifeSci
GoodLifeSci
GoodLifeSci
Renewed Market Optimism @ JPM 2026January 12, 2026What's Ahead for Life Sciences Dealmaking @ JPM 2026January 12, 2026Top 10 FDA Areas We Are Watching @ JPM 2026January 12, 2026Regulatory Considerations for the Next Wave of Development-Stage Transactions @ JPM 2026January 12, 2026
Videos
Videos
Videos
Videos




































